SCHEMBL29927422

SCHEMBL29927422

C[C@H]1CN(C(=O)OCc2ccccc2)CCN1CCC1CCNCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.50
PDK2 Q15119 1/20 0.50
PDK3 Q15120 1/20 0.50
PDK4 Q16654 1/20 0.50
HTR2C P28335 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.44
ITGB3 P05106 2/20 0.44
ITGA2B P08514 2/20 0.44
GRIN2B Q13224 6/20 0.43
CYP2D6 P10635 3/20 0.43
CYP2C9 P11712 3/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SLC29A1 Q99808 1/20 0.42
CHRM1 P11229 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29928438 0.90 HTR2C (0.50) PDK1PDK2PDK3PDK4HTR2C
SCHEMBL29928413 0.86 HTR2C (0.51) PDK1PDK2PDK3PDK4HTR2C
SCHEMBL29928044 0.85 HTR2C (0.50) PDK1PDK2PDK3PDK4HTR2C
SCHEMBL29927363 0.85 PDK1 (0.50) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL27006807 0.83 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ACYP2C19HTT
Hydrochloric Acid SCHEMBL31411038 0.82 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL23867200 0.82 PDK1 (0.53) PDK1PDK2PDK3PDK4HTR2C
SCHEMBL30720915 0.82 PDK1 (0.53) PDK1PDK2PDK3PDK4HTR2C
SCHEMBL29132069 0.81 PDK1 (0.50) PDK1PDK2PDK3PDK4HTR2C
SCHEMBL29927385 0.81 HTR2C (0.58) PDK1PDK2PDK3PDK4HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559506-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 US disclosed
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-10-31 US disclosed
US-11981683-B2 Indazole based compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-05-14 US disclosed
EP-4308557-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2024-01-24 EP disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
WO-2022198112-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360152-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-12559506-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, CLK2 PDK1 2125/4885PDK2 1878/4885PDK3 1663/4885
US-11981683-B2 Indazole based compounds and associated methods of use LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 PDK1 1366/4885PDK2 1007/4885PDK3 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.